Display Settings:

Format

Send to:

Choose Destination
    J Bras Pneumol. 2006 Sep-Oct;32(5):449-60.

    An update on the use of antifungal agents.

    [Article in English, Portuguese]

    Source

    Department of Clinical Medicine, Tropical and Infectious Diseases Division, Ribeirão Preto School of Medicine, Universidade de São Paulo, Ribeirão Preto, Brazil. rmartine@fmrp.usp.br

    Abstract

    We summarize here data regarding the spectrum of action, the pharmacological aspects, the toxicological aspects and the clinical efficacy of liposomal amphotericin B, amphotericin B in colloidal dispersion, amphotericin B lipid complex, voriconazole and caspofungin. We discuss the use of these more recently introduced antifungal agents in terms of their safety, efficiency and cost. We also offer suggestions for the clinical use of these drugs in pulmonary and systemic infections, with an emphasis on the lower toxicity of the lipid formulations of amphotericin B in comparison with conventional medications. In addition, we explore the possibility of using voriconazole as the primary treatment for invasive infections such as aspergillosis, as well as those caused by Scedosporium spp. and Fusarium spp., together with that of using caspofungin to treat disseminated candidiasis and invasive aspergillosis.

    PMID:
    17268750
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for Scientific Electronic Library Online

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk